• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by CapsoVision Inc.

    10/14/25 4:53:31 PM ET
    $CV
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $CV alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    CapsoVision, Inc

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    140935107

    (CUSIP Number)


    07/01/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    140935107


    1Names of Reporting Persons

    Eliyahou Harari
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    84,084.00
    6Shared Voting Power

    4,222,419.00
    7Sole Dispositive Power

    84,084.00
    8Shared Dispositive Power

    4,222,419.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,306,503.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.2 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  The reported total in Rows 5 and 7 includes 84,084 shares of common stock of CapsoVision, Inc. (the "Issuer") directly held by Mr. Harari. The reported total in Rows 6 and 8 includes: (i) 3,186,901 shares of common stock held directly by Harari Family Trust ("Harari Trust"); (ii) 517,759 shares of common stock held directly by The Harari 2010 Children Remainder Trust - DAH ("DAH Trust"); and (iii) 517,759 shares of common stock held directly by The Harari 2010 Children Remainder Trust - MH ("MH Trust"). Mr. Harari serves as trustee of Harari Trust, DAH Trust and MH Trust, and he may be deemed to exercise voting and investment discretion over securities held by those entities in such capacities. The percentage reported in Row 11 was calculated in accordance with Rule 13(d)-3(d)(1)(i) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act") based on an aggregate total of 46,774,067 shares of the Issuer's common stock outstanding as of August 11, 2025, as reported by the Issuer in its quarterly report on Form 10-Q, filed pursuant to Rule 13a-13 or Rule 15d-13 with the Securities and Exchange Commission (the "SEC") on August 14, 2025.


    SCHEDULE 13G

    CUSIP No.
    140935107


    1Names of Reporting Persons

    Britt Harari
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    SWEDEN
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,222,419.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,222,419.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,222,419.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.0 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  The reported total in Rows 6 and 8 includes: (i) 3,186,901 shares of common stock held directly by Harari Family Trust; (ii) 517,759 shares of common stock held directly by DAH Trust; and (iii) 517,759 shares of common stock held directly by MH Trust. Ms. Harari serves as trustee of Harari Trust, DAH Trust and MH Trust, and she may be deemed to exercise voting and investment discretion over securities held by those entities in such capacities. The percentage reported in Row 11 was calculated in accordance with Rule 13(d)-3(d)(1)(i) promulgated under the Exchange Act based on an aggregate total of 46,774,067 shares of the Issuer's common stock outstanding as of August 11, 2025, as reported by the Issuer in its quarterly report on Form 10-Q, filed pursuant to Rule 13a-13 or Rule 15d-13 with the SEC on August 14, 2025.


    SCHEDULE 13G

    CUSIP No.
    140935107


    1Names of Reporting Persons

    Harari Family Trust
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CALIFORNIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,186,901.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,186,901.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,186,901.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.8 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  The reported total in Rows 6 and 8 includes 3,186,901 shares of common stock held directly by Harari Family Trust, for which Mr. Harari and Ms. Harari serve as trustee. The percentage reported in Row 11 was calculated in accordance with Rule 13(d)-3(d)(1)(i) promulgated under the Exchange Act based on an aggregate total of 46,774,067 shares of the Issuer's common stock outstanding as of August 11, 2025, as reported by the Issuer in its quarterly report on Form 10-Q, filed pursuant to Rule 13a-13 or Rule 15d-13 with the SEC on August 14, 2025.


    SCHEDULE 13G

    CUSIP No.
    140935107


    1Names of Reporting Persons

    The Harari 2010 Children Remainder Trust - DAH
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CALIFORNIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    517,759.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    517,759.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    517,759.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.1 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  The reported total in Rows 6 and 8 includes 517,759 shares of common stock held directly by The Harari 2010 Children Remainder Trust - DAH, for which Mr. Harari and Ms. Harari serve as trustee. The percentage reported in Row 11 was calculated in accordance with Rule 13(d)-3(d)(1)(i) promulgated under the Exchange Act based on an aggregate total of 46,774,067 shares of the Issuer's common stock outstanding as of August 11, 2025, as reported by the Issuer in its quarterly report on Form 10-Q, filed pursuant to Rule 13a-13 or Rule 15d-13 with the SEC on August 14, 2025.


    SCHEDULE 13G

    CUSIP No.
    140935107


    1Names of Reporting Persons

    The Harari 2010 Children Remainder Trust - MH
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CALIFORNIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    517,759.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    517,759.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    517,759.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.1 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  The reported total in Rows 6 and 8 includes 517,759 shares of common stock held directly by The Harari 2010 Children Remainder Trust - MH, for which Mr. Harari and Ms. Harari serve as trustee. The percentage reported in Row 11 was calculated in accordance with Rule 13(d)-3(d)(1)(i) promulgated under the Exchange Act based on an aggregate total of 46,774,067 shares of the Issuer's common stock outstanding as of August 11, 2025, as reported by the Issuer in its quarterly report on Form 10-Q, filed pursuant to Rule 13a-13 or Rule 15d-13 with the SEC on August 14, 2025.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    CapsoVision, Inc
    (b)Address of issuer's principal executive offices:

    18805 COX AVENUE SUITE 250, SARATOGA, CALIFORNIA, 95070.
    Item 2. 
    (a)Name of person filing:

    Eliyahou Harari, an individual ("Mr. Harari") Britt Harari, an individual ("Ms. Harari") Harari Family Trust, a trust formed under the laws of California ("Harari Family Trust") The Harari 2010 Children Remainder Trust - DAH, a trust formed under the laws of California ("DAH Trust") The Harari 2010 Children Remainder Trust - MH, a trust formed under the laws of California ("MH Trust")
    (b)Address or principal business office or, if none, residence:

    225 Charcot Ave, San Jose, CA 95131
    (c)Citizenship:

    Mr. Harari and Ms. Harari are citizens of the United States of America and Sweden, respectively. Each of Harari Trust, DAH Trust and MH Trust are formed and established in California.
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP No.:

    140935107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Reference to "beneficial ownership" of securities for purposes of this statement (this "Statement") shall be understood to refer to beneficial ownership as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). As of August 14, 2025, the Reporting Persons may be deemed to beneficially own an aggregate 4,306,503 shares of the Issuer's capital stock. As of August 14, 2025, Mr. Harari was the direct beneficial owner of 84,084 of the shares of the Issuer's securities described in the preceding paragraph and the indirect beneficial owner of: (i) 3,186,901 shares of common stock directly held by Harari Trust; (ii) 517,759 shares of common stock held directly by DAH Trust; and (iii) 517,759 shares of common stock held directly by MH Trust. Mr. Harari serves as trustee of the Harari Trust, the DAH Trust and the MH Trust, and he may be deemed to exercise voting and investment discretion over securities held by those entities in such capacities. As of August 14, 2025, Ms. Harari, Mr. Harari's spouse, was the indirect beneficial owner of: (i) 3,186,901 shares of common stock directly held by Harari Trust; (ii) 517,759 shares of common stock held directly by DAH Trust; and (iii) 517,759 shares of common stock held directly by MH Trust. Ms. Harari serves as trustee of the Harari Trust, the DAH Trust and the MH Trust, and she may be deemed to exercise voting and investment discretion over securities held by those entities in such capacities. Additionally, as of August 14, 2025, each of the following Reporting Persons may also be deemed to share beneficial ownership with Mr. Harari or Ms. Harari over the following portions of the aggregate number of securities described in the second paragraph of this Item 4(a): (i) Harari Trust directly beneficially owns 3,186,901 shares of common stock; (ii) DAH Trust directly beneficially owns 517,759 shares of common stock; and (iii) MH Trust directly beneficially owns 517,759 shares of common stock.
    (b)Percent of class:

    Mr. Harari 9.2% Ms. Harari 9.0% Harari Family Trust 6.8% DAH Trust 1.1% MH Trust 1.1%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Mr. Harari 84,084 Ms. Harari 0 Harari Family Trust 0 DAH Trust 0 MH Trust 0

     (ii) Shared power to vote or to direct the vote:

    Mr. Harari 4,222,419 Ms. Harari 4,222,419 Harari Family Trust 3,186,901 DAH Trust 517,759 MH Trust 517,759

     (iii) Sole power to dispose or to direct the disposition of:

    Mr. Harari 84,084 Ms. Harari 0 Harari Family Trust 0 DAH Trust 0 MH Trust 0

     (iv) Shared power to dispose or to direct the disposition of:

    Mr. Harari 4,222,419 Ms. Harari 4,222,419 Harari Family Trust 3,186,901 DAH Trust 517,759 MH Trust 517,759

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Eliyahou Harari
     
    Signature:/s/ Jack Hayden
    Name/Title:Attorney-in-fact*
    Date:10/09/2025
     
    Britt Harari
     
    Signature:/s/ Jack Hayden
    Name/Title:Attorney-in-fact*
    Date:10/09/2025
     
    Harari Family Trust
     
    Signature:/s/ Jack Hayden
    Name/Title:Attorney-in-fact*
    Date:10/09/2025
     
    The Harari 2010 Children Remainder Trust - DAH
     
    Signature:/s/ Jack Hayden
    Name/Title:Attorney-in-fact*
    Date:10/09/2025
     
    The Harari 2010 Children Remainder Trust - MH
     
    Signature:/s/ Jack Hayden
    Name/Title:Attorney-in-fact*
    Date:10/09/2025

    Comments accompanying signature:  * Jack Hayden is signing on behalf of each reporting person as attorney-in-fact pursuant to powers of attorney filed as attachments hereto, and each power of attorney is hereby incorporated by reference herein.
    Get the next $CV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CV

    DatePrice TargetRatingAnalyst
    7/28/2025$5.00Speculative Buy
    The Benchmark Company
    7/28/2025$6.00Buy
    Roth Capital
    More analyst ratings

    $CV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    The Benchmark Company initiated coverage on CapsoVision with a new price target

    The Benchmark Company initiated coverage of CapsoVision with a rating of Speculative Buy and set a new price target of $5.00

    7/28/25 8:55:56 AM ET
    $CV
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Roth Capital initiated coverage on CapsoVision with a new price target

    Roth Capital initiated coverage of CapsoVision with a rating of Buy and set a new price target of $6.00

    7/28/25 8:55:14 AM ET
    $CV
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Tsai Chen Lung bought $83 worth of shares (20 units at $4.17) (SEC Form 4)

    4/A - CapsoVision, Inc (0001378325) (Issuer)

    2/6/26 4:37:48 PM ET
    $CV
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Shen Ching Hang

    3 - CapsoVision, Inc (0001378325) (Issuer)

    3/30/26 3:52:57 PM ET
    $CV
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Harari Eliyahou Et Al

    3 - CapsoVision, Inc (0001378325) (Issuer)

    3/26/26 9:46:58 PM ET
    $CV
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Tsai Chen Lung

    4 - CapsoVision, Inc (0001378325) (Issuer)

    3/23/26 6:29:25 PM ET
    $CV
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CV
    SEC Filings

    View All

    SEC Form 10-K filed by CapsoVision Inc.

    10-K - CapsoVision, Inc (0001378325) (Filer)

    3/26/26 4:44:07 PM ET
    $CV
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CapsoVision Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - CapsoVision, Inc (0001378325) (Filer)

    3/26/26 4:08:52 PM ET
    $CV
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CapsoVision Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Entry into a Material Definitive Agreement, Regulation FD Disclosure

    8-K - CapsoVision, Inc (0001378325) (Filer)

    3/20/26 8:04:37 AM ET
    $CV
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CapsoVision Reports Fourth Quarter and Full Year 2025 Financial Results

    SARATOGA, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Highlights Fourth quarter 2025 revenue was $3.9 million, a 13% increase over the fourth quarter of 2024. Full year 2025 revenue was $13.6 million, a 15% increase compared to full year 2024.New accounts grew 16% in the fourth quarter of 2025 over the comparable quarter in 2024. Full year 2025 new accounts grew 21% compared to full year 2024.CapsoCam Plus® used by over 161,000 patients as of

    3/26/26 4:05:00 PM ET
    $CV
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CapsoVision Announces $14 Million Private Placement Financing

    SARATOGA, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (the "Company") (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced the closing of a $14 million private placement in public equity financing (the "Private Placement") pursuant to a securities purchase agreement entered into by the Company with selected accredited investors on March 16, 2026 for such investors to purchase shares (the "Shares") of common stock of the Company. Pursuant to the securities purchase agreement, the Company has agreed to sell 2,867,089 shares of common stock of the Company, with par value $0.001 per

    3/20/26 8:00:00 AM ET
    $CV
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CapsoVision to Release Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 26, 2026

    SARATOGA, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the company will release fourth quarter and full year 2025 financial results on Thursday, March 26, 2026, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm PT / 4:30 pm ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and refere

    3/12/26 4:05:00 PM ET
    $CV
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CV
    Financials

    Live finance-specific insights

    View All

    CapsoVision to Release Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 26, 2026

    SARATOGA, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the company will release fourth quarter and full year 2025 financial results on Thursday, March 26, 2026, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm PT / 4:30 pm ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and refere

    3/12/26 4:05:00 PM ET
    $CV
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CapsoVision to Release Third Quarter 2025 Financial Results on Thursday, November 13, 2025

    SARATOGA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the company will release third quarter 2025 financial results on Thursday, November 13, 2025, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm PT / 4:30 pm ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and referencing conferen

    10/30/25 4:05:00 PM ET
    $CV
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CapsoVision to Release Second Quarter 2025 Financial Results on Thursday, August 14, 2025

    - Conference Call Scheduled for Thursday, August 14, 2025 at 4:30 pm ET - SARATOGA, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence ("AI") technologies that are deployed in its capsule endoscopy solutions, today announced that the company will release second quarter 2025 financial results on Thursday, August 14, 2025, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm PT / 4:30 pm ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the c

    7/31/25 4:05:00 PM ET
    $CV
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care